Datapoint: FDA Approves Genentech’s Lunsumio in Follicular Lymphoma

January 12

The FDA last month approved Genentech’s Lunsumio as a third-line treatment for follicular lymphoma, pitting the bispecific antibody against the CAR-T class: Bristol Myers Squibb’s Breyanzi, Gilead’s Yescarta and Novartis’ Kymriah. Genentech says Lunsumio has an advantage over its CAR-T rivals as an “off-the-shelf, accessible treatment option” that can be administered in an outpatient setting. Under the medical benefit, Breyanzi is currently the most advantaged of the three CAR-T therapies in the treatment of follicular lymphoma, holding covered or better status for 83% of all insured lives.

SOURCE: MMIT Analytics, as of 1/9/23